In the year just past, Alzheimer’s researchers, families, and stakeholders felt renewed hope that new treatments might be within grasp. This update from the Alz Forum summarises how some of the increased funding might be spent.
Developing computational algorithms & machine-learning techniques, to transform cross-sectional imaging data to a longitudinal picture and reconstruct the sequence of disease progression.
Check out the “booths” in this new section of the AlzForum to learn about products and services that could accelerate your research.
The notorious amyloid precursor protein, central to Alzheimer’s disease pathogenesis, sports a new look on Alzforum’s Mutations database.
Brush, Floss, Take a Protease Inhibitor? Do periodontal bacteria cause some cases of Alzheimer’s disease? Scientists at one start-up think so.
In AD, tau tangles correlate closely with neurodegeneration, but how they work their mischief remains unclear… or does it?
Though Aβ-targeted therapies hogged the limelight at this year’s CTAD Conference a large handful of smaller studies had findings to report, as well.
Around 140 scientists gathered in Rungstedgaard, north of Copenhagen, Denmark, May 5–9 for the biannual Brain Conference organised by the Federation of European Neuroscience Societies and the Lundbeck Foundation. This article from the Alz Forum shares news from the event.
Merck shook the field with news that people on verubecestat scored worse than those on placebo – find out more in this post from AlzForum
GV-971, aka oligomannate, receives conditional approval in China for the treatment of mild to moderate Alzheimer’s disease.
3 years ago Michal Schwartz at the Weizmann Institute of Science, deployed an immune-boosting approach pioneered for cancer in a mouse model of Alzheimer’s disease. How has this progressed?
Researchers from University College London have strengthened the case that certain medical procedures can transfer amyloid pathology between people.